Financial Forecasts - The company revised its 2024 net profit forecast to a range of 53.5 million to 63.5 million CNY, down from the previous estimate of 45 million to 65 million CNY [3]. - The adjusted net profit after deducting non-recurring gains and losses is now expected to be between 25.88 million and 35.88 million CNY, compared to the prior estimate of 26.1 million to 39.1 million CNY [4]. Revenue and Expenses - The company will reduce revenue by 40 million CNY due to indications of contract termination in R&D projects [6]. - An increase in income tax expenses by 45 million CNY is attributed to the cautious recognition of deferred tax assets related to deductible temporary differences [6]. - The company has recognized a decrease in pre-tax profit by 10 million CNY due to specific provisions for bad debts on accounts receivable [6]. Communication and Reporting - The board emphasizes the importance of improving communication with the accounting firm to enhance the accuracy of future performance forecasts [7]. - The financial data for the performance forecast revision is based on calculations from the finance department, with detailed figures to be disclosed in the 2024 annual report [8].
百诚医药(301096) - 2024 Q4 - 年度业绩预告